A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors

This is a single-arm, phase II study to evaluate the efficacy and safety of Sacituzumab Tirumotecan, a TROP2-directed antibody-drug conjugate, in patients with advanced thymic epithelial tumors who have received second-line or later therapy.

NCT Number	NCT07343453
Lead Sponsor	Sun Yat-sen University
Conditions	Thymic Epithelial Tumors, Advanced Stage, Second-line Therapy
Enrollment	38 participants
Start Date	2025-12-22
Primary Completion	2027-12-22 (estimated)
Study Completion	2029-12-22 (estimated)
Updated on ClinicalTrials.gov	2026-01-15